Table 2.

Clinical characteristics at baseline of 212 AAV patients with renal involvement: differences between PR3-ANCA–positive patients, MPO-ANCA–positive patients, and PR3-ANCA–negative and MPO-ANCA–negative patients (statistical analysis for PR3 versus MPO)

CharacteristicPR3MPOP ValueANCA Negative
Number138659
Age (mean)56±1661±150.02a60±15
Sex91310.01a4
Comorbidity
 Hypertension300.231
 Diabetes mellitus870.210
 Cardiovascular disease1080.242
 Autoimmune diseasesb350.061
 Malignancy1220.141
Diagnosis
 Granulomatosis with polyangiitis12273
 Microscopic polyangiitis13381
 Renal limited vasculitis3205
Ear, nose, and throat10615<0.001a3
Pulmonary3180.081
Birmingham Vasculitis Activity Score26 (7–48)18 (10–32)<0.001a18 (12–25)
Creatinine (mg/dl)(3.04±2.84)4.82±4.22<0.001a3.54±2.75
C-reactive protein13±9.57.2±6.5<0.001a4.3± 4.2
Proteinuria (g/24 h)1.62.40.004a1.4
Renal replacement therapy28200.101
Plasmapheresis33150.900
  • Data are presented as the number, mean ± SD, or median (range). PR3, proteinase 3; MPO, myeloperoxidase; AAV, ANCA-associated vasculitis.

  • a Statistically significant.

  • b Concomitant autoimmune diseases included hypothyroidism (n=2) and psoriasis (n=1) in PR3-ANCA–positive patients; hypothyroidism (n=2), hyperthyroidism (n=1), sarcoidosis (n=1), and Sjögren’s syndrome (n=1) in MPO-ANCA–positive patients; and hyperthyroidism (n=1) in ANCA–negative patients.